{"id":123853,"date":"2015-06-30T17:56:46","date_gmt":"2015-06-30T17:56:46","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=123853"},"modified":"2015-06-30T17:56:46","modified_gmt":"2015-06-30T17:56:46","slug":"un-nou-medicament-revolutionar-impotriva-cancerului-pulmonar-administrat-gratuit-in-marea-britanie","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=123853","title":{"rendered":"Un nou medicament revolu\u0163ionar \u00eempotriva cancerului pulmonar, administrat gratuit \u00een Marea Britanie"},"content":{"rendered":"<p>\nMedicamentul a devenit disponibil gra\u0163ie unei politici adoptate de guvernul britanic ce permite autorizarea \u00een regim de urgen\u0163\u0103 a substan\u0163elor care au poten\u0163ialul de a salva vie\u0163i omene\u015fti, evit\u00e2nd astfel procesul obi\u015fnuit de licen\u0163iere a noilor tratamente medicale, care dureaz\u0103 de obicei mai mul\u0163i ani, informeaz\u0103 <a href=\"http:\/\/dailymail.co.uk\" target=\"_blank\">dailymail.co.uk<\/a>.<\/p>\n<p>\n<strong>Administrat sub forma unui vaccin la fiecare dou\u0103 s\u0103pt\u0103m\u00e2ni, medicamentul Nivolumab \u00eenva\u0163\u0103 sistemul imunitar din organismul pacientului s\u0103 identifice \u015fi s\u0103 atace celulele canceroase.<\/strong><\/p>\n<p>\nRezultatele studiilor preliminare au ar\u0103tat c\u0103 efectele benefice continu\u0103 timp de mai mul\u0163i ani dup\u0103 \u00eencheierea tratamentului. Exper\u0163ii \u00een domeniu afirm\u0103 c\u0103 o astfel de imunoterapie a deschis o &#8220;er\u0103 nou\u0103&#8221; \u00een lupta \u00eempotriva cancerului. Testele preliminare au sugerat faptul c\u0103 noul medicament dubleaz\u0103 \u015fansele de supravie\u0163uire ale pacien\u0163ilor.<\/p>\n<p>\n<strong>\u00cencep\u00e2nd de mar\u0163i, medicii britanici vor putea s\u0103 ofere medicamentul Nivolumab pacien\u0163ilor cu cancer pulmonar \u00een stare avansat\u0103, pentru care interven\u0163ia chirurgical\u0103 nu mai reprezint\u0103 o op\u0163iune valid\u0103. Costurile vor fi suportate de produc\u0103torul medicamentului, compania Bristol-Myers Squibb.<\/strong><\/p>\n<p>\nTerapia difer\u0103 de tratamentele &#8220;p\u0103tur\u0103&#8221;, a\u015fa cum sunt denumite chimioterapia \u015fi radioterapia, care ucid toate celulele din zonele afectate, inclusiv cele s\u0103n\u0103toase.<\/p>\n<p>\nAcest fapt \u00eenseamn\u0103 c\u0103 pacien\u0163ii vor prezenta mai pu\u0163ine efecte secundare &#8211; oboseal\u0103, ame\u0163eal\u0103, c\u0103derea p\u0103rului \u015fi infec\u0163ii -, ce apar din cauza distrugerii celulelor s\u0103n\u0103toase.<\/p>\n<p>\nUnii dintre pacien\u0163ii diagnostica\u0163i anterior cu cancer de piele \u00een stadiu terminal au putut deja s\u0103 \u00ee\u015fi reia activitatea \u015fi s\u0103 revin\u0103 la locurile lor de munc\u0103 dup\u0103 ce au urmat aceast\u0103 imunoterapie. Ace\u015fti pacien\u0163i au nevoie doar de o injec\u0163ie cu Nivolumab la c\u00e2teva luni.<\/p>\n<p>\n\u00cen schimb, cancerul pulmonar este una dintre formele de cancer cu cea mai mare rat\u0103 de mortalitate din lume. Doar 5% dintre pacien\u0163i supravie\u0163uiesc timp de zece ani dup\u0103 diagnosticare.<\/p>\n<p>\nCancerul pulmonar ocup\u0103, de asemenea, locul al doilea \u00een topul celor mai frecvente tipuri de cancer &#8211; dup\u0103 cancerul mamar la femei \u015fi cel de prostat\u0103 la b\u0103rba\u0163i. Aproximativ 43.000 de cazuri noi de cancer pulmonar sunt diagnosticate \u00een fiecare an \u00een Marea Britanie.<\/p>\n<p>\nNivolumab este al treilea medicament care devine disponibil pentru pacien\u0163ii britanici prin intermediul Early Access To Medicines Scheme, o procedur\u0103 de aprobare \u00een regim de urgen\u0163\u0103 a noilor tratamente.<\/p>\n<p>\nProduc\u0103torul transmite spre consultare datele \u015ftiin\u0163ifice aferente noului medicament unui grup de exper\u0163i de la Medicines and Healthcare Products Regulatory Agency. Dac\u0103 aceast\u0103 agen\u0163ie se declar\u0103 satisf\u0103cut\u0103 de acele date \u015fi consider\u0103 c\u0103 medicamentul este benefic pentru oameni, f\u0103r\u0103 s\u0103 cauzeze efecte secundare grave, atunci tratamentul devine disponibil pentru pacien\u0163i. Costurile sunt acoperite de produc\u0103tor p\u00e2n\u0103 c\u00e2nd noul medicament este aprobat oficial pe pia\u0163\u0103 prin procedura obi\u015fnuit\u0103.<\/p>\n<p>\nStudiul preliminar, realizat pe 272 de pacien\u0163i, a relevat faptul c\u0103 42% dintre aceste persoane tratate cu Nivolumab erau \u00eenc\u0103 \u00een via\u0163\u0103 la un an dup\u0103 \u00eenceperea tratamentului. \u00cen compara\u0163ie, acest procent a fost de doar 24% \u00een r\u00e2ndul pacien\u0163ilor care au f\u0103cut chimioterapie. Unii dintre pacien\u0163ii care au primit acest medicament erau \u00eenc\u0103 \u00een via\u0163\u0103 \u015fi dup\u0103 doi ani de la debutul terapiei.<\/p>\n<p>\nCompania Bristol-Myers Squibb spune c\u0103 peste 10.000 de pacien\u0163i din Marea Britanie ar putea avea de beneficiat de pe urma acestor injec\u0163ii cu Nivolumab. Luna trecut\u0103, mai mul\u0163i exper\u0163i \u00een oncologie au spus c\u0103 imunoterapia reprezint\u0103 cea mai mare descoperire medical\u0103 de la inventarea chimioterapiei.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un nou medicament revolu\u0163ionar \u00eempotriva cancerului pulmonar, Nivolumab, care \u00eenva\u0163\u0103 organismul pacien\u0163ilor s\u0103 depisteze \u015fi s\u0103 distrug\u0103 celulele canceroase, dubl\u00e2nd \u015fansele de supravie\u0163uire ale bolnavilor, este administrat gratuit, \u00eencep\u00e2nd de mar\u0163i, \u00een Marea Britanie.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[40948,40949],"class_list":["post-123853","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-cancer-pulmonar","tag-nivolumab"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/123853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=123853"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/123853\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=123853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=123853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=123853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}